Equities

Sichuan Hebang Biotechnology Co Ltd

603077:SHH

Sichuan Hebang Biotechnology Co Ltd

Actions
Basic MaterialsChemicals
  • Price (CNY)1.67
  • Today's Change-0.01 / -0.60%
  • Shares traded28.50m
  • 1 Year change-27.07%
  • Beta--
Data delayed at least 15 minutes, as of Sep 23 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,9054,5451,768
Total Receivables, Net2,1962,8571,675
Total Inventory4,4032,076912
Prepaid expenses191195128
Other current assets, total15946159
Total current assets9,8559,7194,643
Property, plant & equipment, net9,6849,5708,295
Goodwill, net1,8381,8381,904
Intangibles, net2,3012,1711,967
Long term investments667677662
Note receivable - long term2011--
Other long term assets----417
Total assets24,54224,10317,922
LIABILITIES
Accounts payable1,5441,7591,156
Accrued expenses11411152
Notes payable/short-term debt1,5001,3391,171
Current portion long-term debt/capital leases34516696
Other current liabilities, total167359647
Total current liabilities3,6703,7343,123
Total long term debt456430105
Total debt2,3011,9351,373
Deferred income tax1239640
Minority interest643645392
Other liabilities, total757917
Total liabilities4,9674,9843,677
SHAREHOLDERS EQUITY
Common stock8,8318,8318,831
Additional paid-in capital1,1251,095470
Retained earnings (accumulated deficit)10,2189,3205,652
Treasury stock - common(650)(150)(700)
Unrealized gain (loss)296.83--
Other equity, total2316(8.62)
Total equity19,57519,11814,245
Total liabilities & shareholders' equity24,54224,10317,922
Total common shares outstanding8,5128,7258,831
Treasury shares - common primary issue3201060
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.